Time to Move on: HLA Matching Should Be Reconsidered in Modern Deceased Donor Kidney Allocation.

Transplant Direct

Surgical Services, John Hunter Hospital, Hunter New England Local Health District, Newcastle, NSW, Australia.

Published: March 2022

Unlabelled: HLA matching has been the cornerstone of deceased donor kidney allocation policies worldwide but can lead to racial inequity. Although HLA matching has been shown to improve clinical outcomes, the long-term impacts of nonallogenic factors are being increasingly recognized. This has led some transplant programs to include points for nonallogenic factors, for example, age. Our study looks at long-term graft and patient outcomes based on allocation cohorts rather than individual number of HLA mismatches.

Methods: Using the Australia and New Zealand Dialysis and Transplant Registry, we analyzed 7440 adult deceased donor transplant events from 2000 to 2018. Transplants were classified as HLA matched or nonmatched according to the OrganMatch score and the local allocation algorithms. Graft function was studied with linear mixed modeling and graft rejection with logistic and binomial regression. Time to graft failure and recipient survival were examined with Kaplan-Meier curve and Cox regression models.

Results: Forty percent of transplants were HLA matched. Mean glomerular filtration rate was 1.76 mL/min/1.73 m higher in the matched transplants ( < 0.001). Matched transplants had longer time to graft failure (15.9 versus 12.7 y;  < 0.001) and improved recipient survival (risk of death hazard ratio, 0.83;  = 0.003). Matched recipients spent less time on dialysis (28.1 versus 44.8 mo;  < 0.001), and this significantly contributed to the benefits seen in graft loss and recipient survival. Caucasian recipients were more likely to receive a matched transplant than non-Caucasians.

Conclusions: Matched transplants showed benefits in graft and recipient outcomes; however, some of these results were of small magnitude, whereas others seemed to be due in part to a reduction in time on dialysis. The benefit for the matched cohort came at the expense of the nonmatched cohort, who spent longer on dialysis and were more likely to be of a minority racial background.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8966965PMC
http://dx.doi.org/10.1097/TXD.0000000000001295DOI Listing

Publication Analysis

Top Keywords

hla matching
12
deceased donor
12
donor kidney
8
kidney allocation
8
nonallogenic factors
8
hla matched
8
hla
6
time move
4
move hla
4
matching reconsidered
4

Similar Publications

Background: Vascular thymus transplantation has been explored in animal models but remains untested in humans. Current approaches to congenital athymia involve avascular transplantation of allogeneic thymic tissue, which may delay immune recovery. Building on animal studies, we propose revascularization of thymic tissue in a human model.

View Article and Find Full Text PDF

ATAD2 is a potential immunotherapy target for patients with small cell lung cancer harboring HLA-A∗0201.

EBioMedicine

January 2025

State Key Laboratory of Molecular Oncology, CAMS Key Laboratory of Translational Research on Lung Cancer, Department of Medical Oncology, National Cancer Centre/National Clinical Research Centre for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences Peking Union Medical College, Beijing, 100021, China. Electronic address:

Background: Small cell lung cancer (SCLC) represents a highly aggressive neuroendocrine tumour with a dismal prognosis. Currently, the identification of a specific tumour antigen that can facilitate immune-based therapies for SCLC remains elusive.

Methods: We employed liquid chromatography-tandem mass spectrometry (LC-MS/MS) to analyse cancer/testis antigens (CTAs) in SCLC cell lines and human tumour specimens.

View Article and Find Full Text PDF

Objective: Thrombocytopenia is a common complication of hematopoietic stem-cell transplantation (HSCT), though many patients will become immune refractory to platelet transfusions over time. We built and evaluated an electronic health record (EHR)-integrated, standards-based application that enables blood-bank clinicians to match platelet inventory with patients using data previously not available at the point-of-care, like human leukocyte antigen (HLA) data for donors and recipients.

Materials And Methods: The web-based application launches as an EHR-embedded application or as a standalone application.

View Article and Find Full Text PDF

Background: Recurrence of blood malignancy is the major cause of mortality after hematopoietic cell transplantation. NKG2 receptor/HLA-E ligand complexes play a fundamental role in the surveillance and elimination of transformed cells but their role in the control of leukemia in transplantation is unknown.

Objective: We tested the hypothesis that gene variation of patient and/or donor HLA-E ligand and donor NKG2C-NKG2A receptors are associated with the risks of relapse and mortality (primary endpoints) and GVHD and non-relapse mortality (secondary endpoints) after haploidentical transplantation.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!